NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148453&fro ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. on behalf of shareholders who purchased common stock between February 16, 2023, and February 12, 2025, alleging misleading statements and operational inefficiencies that negatively impacted the company's financial performance [1][5]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical made false and misleading statements regarding customer demand and product performance, particularly in its High-Value Products portfolio [5]. - It is alleged that the SmartDose device, intended as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [5]. - The lawsuit also highlights risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts, as a result of margin pressures [5]. Group 2: Participation Information - Shareholders who purchased stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by July 7, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements, ranking in the top 4 since 2013 [4].

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Phar ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a memb ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147742&fro ...

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147732&from=4 CLA ...

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and operational inefficiencies impacting financial performance [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., and covers purchasers of common stock between February 16, 2023, and February 12, 2025 [1]. - Investors have until July 7, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and the performance of its high-margin products [3]. Group 2: Allegations Against West Pharmaceutical - The lawsuit claims that West Pharmaceutical was experiencing significant destocking in its High-Value Products portfolio, contrary to its public statements [3]. - The SmartDose device, which was expected to be a high-margin growth product, is alleged to have caused profit margin dilution due to operational inefficiencies [3]. - The company’s exit from continuous glucose monitoring contracts is cited as a risk stemming from margin pressures [3]. Group 3: Financial Impact and Stock Performance - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to the loss of two major customers transitioning to in-house manufacturing and the decision not to participate in future contracts [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

NEW YORK, May 9, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. ("West" or "the Company") (NYSE: WST) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired West se ...

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a membe ...